| Literature DB >> 17476350 |
Abstract
The transfusion of T cells, also called adoptive T cell therapy, is an effective treatment for viral infections and has induced regression of cancer in early-stage clinical trials. However, recent advances in cellular immunology and tumor biology are guiding new approaches to adoptive T cell therapy. For example, use of engineered T cells is being tested as a strategy to improve the functions of effector and memory T cells, and manipulation of the host to overcome immunotoxic effects in the tumor microenvironment has led to promising results in early-stage clinical trials. Challenges that face the field and must be addressed before adoptive T cell therapy can be translated into routine clinical practice are discussed.Entities:
Mesh:
Year: 2007 PMID: 17476350 PMCID: PMC1857246 DOI: 10.1172/JCI31446
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808